Atterocor, Inc. (Atterocor)

Oncology Corporate Profile

HQ Location

301 N. Main St., Suite 100
Ann Arbor, MI 48104

Company Description

Atterocor is a drug development company focused on a novel treatment for adrenal cancer. The company is accelerating the development of a new adrenal-targeting therapy for the treatment of adrenocortical carcinoma (ACC) patients. ACC is a rare disease with a poor prognosis, extremely limited treatment options and significant unmet medical need.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ATR-101ACAT 1 inhibitorAdrenocortical carcinoma (ACC)I


Recent News Headlines

There are no news items to display